TITLE

COMMENTARY: Review: Pharmacotherapy improves cognitive symptoms in dementia

AUTHOR(S)
Hirsch, Calvin
PUB. DATE
January 2005
SOURCE
ACP Journal Club;Jan/Feb2005, Vol. 142 Issue 1, p14
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article reports that pharmacotherapy improves cognitive symptoms in dementia. Pharmacotherapy of dementia involves treatment aimed both at the underlying disease and associated behavioral problems that occur during the course of the dementia. Meta-analysis of the results from pooled trials suggests that • . donepezil, rivastigmine and galantamine have similar, small effect sizes for short-term cognitive improvement in Alzheimer disease. The concern that risperidone and olanzapine increase the risk for stroke has not been supported by a retrospective population-based cohort study of patients prescribed these medications.
ACCESSION #
15851783

 

Related Articles

  • Studies show that drugs treating neuropsychiatric symptoms in patients with dementia can be lethal and not all that effective.  // Canadian Nursing Home;Jun/Jul2005, Vol. 16 Issue 2, p21 

    Discusses research on effective drug therapies for control of neuropsychiatric symptoms in patients with dementia. Identification of neuropsychiatric symptoms in patients with Alzheimer's disease, vascular dementia or Lewy body disease; Types of antipsychotic or neuroleptic drugs; Efficacy of...

  • Review: Pharmacotherapy improves cognitive symptoms in dementia. Santaguida, L. // ACP Journal Club;Jan/Feb2005, Vol. 142 Issue 1, p14 

    The article reports that pharmacotherapy improves cognitive symptoms in dementia. Studies were selected if they were English-language parallel-group randomized controlled trials of pharmacologic agents in patients greater than 18 years of age with dementia. In patients with dementia, several...

  • Memantine. Jarvis, Blair; Figgitt, David P. // Drugs & Aging;2003, Vol. 20 Issue 6, p465 

    â–´ Memantine, an uncompetitive antagonist with moderate affinity for NMDA receptors, demonstrates voltage-dependency and relatively fast on/off receptor kinetics. â–´ Memantine 20 mg/day significantly slowed the rate of deterioration in outpatients with moderate to severe Alzheimer's...

  • Genetic discoveries as the basis of personalized therapy: rosiglitazone treatment of Alzheimer's disease. Hsueh, W. // Pharmacogenomics Journal;2006, Vol. 6 Issue 4, p222 

    Discusses a study which examined the application of rosiglitazone or placebo in treating Alzheimer's disease (AD). Experimental results on the effects of placebo on patients with AD; Mechanisms of action of rosiglitazone in AD; Findings that could explain the relationship between diabetes and AD.

  • Cognitive Pharmacotherapy of Alzheimer's Disease and Other Dementias. Herrmann, Nathan // Canadian Journal of Psychiatry;Oct2002, Vol. 47 Issue 8, p715 

    Objective: The objective of this paper is to review the randomized controlled trials (RCTs) on the pharmacotherapy of Alzheimer's disease and other dementias and to provide evidence-based recommendations for treatment of the cognitive impairment associated with these disorders. Method: A Medline...

  • GINKGO NO-GO.  // Nutrition Action Health Letter;Jan/Feb2009, Vol. 36 Issue 1, p8 

    The article discusses research being done on the effectiveness of ginkgo in preventing dementia. It references a study published in the 2008 issue of the "Journal of the American Medical Association." Investigators randomly assigned 482 people with mild cognitive impairment and 2,587 people with...

  • Carphology by Rajendra.  // Practical Neurology (BMJ Publishing Group);Apr2009, Vol. 9 Issue 2, p127 

    The article reports on a study regarding the effectiveness of ginkgo biloba in reducing occurrences of dementia or Alzheimer's disease in older people. It states that over 3,000 community volunteers aged 75 years or older undergone the randomized, placebo-controlled trial. It revealed that...

  • Defining Treatment Response to Donepezil in AlzheimerÂ’s Disease: Responder Analysis of Patient-Level Data from Randomized, Placebo-Controlled Studies. Burns, Alistair; Yeates, Andrew; Akintade, Latif; del Valle, Megan; Zhang, Richard Y.; Schwam, Elias M.; Perdomo, Carlos A. // Drugs & Aging;2008, Vol. 25 Issue 8, p707 

    BACKGROUND: Defining treatment success in progressive diseases, such as Alzheimer’s disease (AD), can be challenging. OBJECTIVE: To explore the impact of employing different criteria to define a treatment ‘responder’ using analyses of patient-level data from randomized,...

  • THE EFFECT OF THERAPEUTIC TOUCH ON BEHAVIORAL SYMPTOMS OF PERSONS WITH DEMENTIA. Woods, Diana Lynn; Craven, Ruth F.; Whitney, Joie // Alternative Therapies in Health & Medicine;Jan/Feb2005, Vol. 11 Issue 1, p66 

    Background Approximately 80% of nursing home residents who suffer from Alzheimer's disease and related dementia develop behavioral symptoms of dementia. Given the deleterious side effects of pharmacologic therapy in this population there is an urgent need for clinical trials of nonpharmacologic...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics